IRVINE, Calif., Aug. 27 /PRNewswire-FirstCall/ -- IDM Pharma (Nasdaq: IDMI) today announced that Jeffrey W. Sherman, M.D., F.A.C.P. has been appointed as the Company's Chief Medical Officer and Senior Vice President of Research and Development. Dr. Sherman will join the Company in September and will report to President and CEO Timothy P. Walbert.
Dr. Sherman brings close to 20 years of pharmaceutical experience to IDM Pharma and will lead the regulatory and clinical strategy for L-MTP-PE and the development of the Company's pipeline, including UVIDEM and IDM-2101. He joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he served as Vice President of Clinical Science and was focused on developing Takeda's oncology pipeline.
"Dr. Sherman's depth of oncology experience and pharmaceutical and biotechnology expertise will be an asset as we continue to work through the regulatory process with L-MTP-PE and develop our oncology pipeline," said Timothy P. Walbert, President and Chief Executive Officer of IDM Pharma, Inc. "In the near-term, Dr. Sherman will oversee the preparation and submission of the L-MTP-PE NDA amendment in the US and work closely with regulatory authorities in Europe to complete the L-MTP-PE review process."
About Dr. Jeffrey Sherman
Dr. Sherman joins IDM Pharma from Takeda Global Research & Development Center, Inc., a subsidiary of Takeda Pharmaceutical Company Limited, where he served as Vice President of Clinical Science, Oncology. Prior to Takeda, Dr. Sherman served as Chief Medical Officer and Executive Vice President at NeoPharm, Inc. where he was responsible for developing clinical drug research and development strategies.
Before joining NeoPharm, Dr. Sherman held various roles at
Searle/Pharmacia Research and Development, and Medical Marketing, including
Executive Director of Clinical Research and Head of Oncology Medical
|SOURCE IDM Pharma, Inc.|
Copyright©2007 PR Newswire.
All rights reserved